Találati lista | Tudóstér

001-es BibID:	BIBFORM114359
035-os BibID:	(WoS)001065800700001 (Scopus)85179996474
Első szerző:	Taylor, Peter C.
Cím:	Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases / Peter C. Taylor, Ernest Choy, Xenofon Baraliakos, Zoltan Szekanecz, Ricardo M. Xavier, John D. Isaacs, Sander Strengholt, Julie M. Parmentier, Ralph Lippe, Yoshiya Tanaka
Dátum:	2024
ISSN:	1462-0324 1462-0332
Megjegyzések:	Janus kinases (JAKs) are a family of cytosolic tyrosine kinases that regulate cytokine signal transduction, including cytokines involved in a range of inflammatory diseases, such as RA, psoriasis, atopic dermatitis and IBD. Several small-molecule JAK inhibitors (JAKis) are now approved for the treatment of various immune-mediated inflammatory diseases. There are, however, key differences between these agents that could potentially translate into unique clinical profiles. Each JAKi has a unique chemical structure, resulting in a distinctive mode of binding within the catalytic cleft of the target JAK, and giving rise to distinct pharmacological characteristics. In addition, the available agents have differing selectivity for JAK isoforms, as well as off-target effects against non-JAKs. Other differences include effects on haematological parameters, DNA damage repair, reproductive toxicity and metabolism/elimination. Here we review the pharmacological profiles of the JAKis abrocitinib, baricitinib, filgotinib, peficitinib, tofacitinib and upadacitinib.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Rheumatology. - 63 : 2 (2024), p. 298-308. -
További szerzők:	Choy, Ernest Baraliakos, Xenofon Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Xavier, Ricardo M. Isaacs, John D. Strengholt, Sander Parmentier, Julie M. Lippe, Ralph Tanaka, Yoshiya
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: